Clodi, MartinMartinClodiAbrahamian, HeidemarieHeidemarieAbrahamianBrath, HelmutHelmutBrathBrix, JohannaJohannaBrixDrexel, HeinzHeinzDrexelFasching, PeterPeterFaschingFöger, BernhardBernhardFögerFrancesconi, ClaudiaClaudiaFrancesconiFröhlich-Reiterer, ElkeElkeFröhlich-ReitererHarreiter, JürgenJürgenHarreiterHofer, Sabine ESabine EHoferHoppichler, FriedrichFriedrichHoppichlerHuber, JoakimJoakimHuberKaser, SusanneSusanneKaserKautzky-Willer, AlexandraAlexandraKautzky-WillerLechleitner, MonikaMonikaLechleitnerLudvik, BernhardBernhardLudvikLuger, AntonAntonLugerMader, Julia KJulia KMaderPaulweber, BernhardBernhardPaulweberPieber, ThomasThomasPieberPrager, RudolfRudolfPragerRami-Merhar, BirgitBirgitRami-MerharResl, MichaelMichaelReslRiedl, MichaelaMichaelaRiedlRoden, MichaelMichaelRodenSaely, Christoph HChristoph HSaelySchelkshorn, ChristianChristianSchelkshornSchernthaner, GuntramGuntramSchernthanerSourij, HaraldHaraldSourijStechemesser, LarsLarsStechemesserStingl, HaraldHaraldStinglToplak, HermannHermannToplakWascher, Thomas CThomas CWascherWeitgasser, RaimundRaimundWeitgasserWinhofer-Stöckl, YvonneYvonneWinhofer-StöcklZlamal-Fortunat, SandraSandraZlamal-Fortunat2024-10-282024-10-282019-05https://boris-portal.unibe.ch/handle/20.500.12422/184209Hyperglycemia significantly contributes to complications in patients with diabetes mellitus. While lifestyle interventions remain cornerstones of disease prevention and treatment, most patients with type 2 diabetes will eventually require pharmacotherapy for glycemic control. The definition of individual targets regarding optimal therapeutic efficacy and safety as well as cardiovascular effects is of great importance. In this guideline we present the most current evidence-based best clinical practice data for healthcare professionals.deDiabetes mellitus Type 2 Glucose lowering Therapy600 - Technology::610 - Medicine & healtharticle10.7892/boris.1363903098014810.1007/s00508-019-1471-z